Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
RX108 / Suzhou NeuPharma
ChiCTR2100052066: Safety and efficacy of RX108 delivered via drug eluting beads transarterial chemoembolization (DEB-TACE) in patients with primary hepatocellular carcinoma	Recruiting	2	20		RX108 delivered via drug eluting beads transarterial chemoembolization (DEB-TACE)	Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, Suzhou NeuPharma Co., Ltd.	Primary hepatocellular carcinoma
ACTRN12623000307606: Phase I study to evaluate Safety and Tolerability of RX108-A Tablets in Patients with advanced Cancer	Recruiting	1	20			NeuPharma Pty Ltd, NeuPharma Pty Ltd	Locally Advanced or Metastatic Solid Tumors
NCT03646071: A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors	Recruiting	1	80	US	RX108	NeuPharma, Inc.	Locally Advanced Solid Tumors, Metastatic Solid Tumors	08/23	12/23
ACTRN12616000008426: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RX108 in Patients with Advanced or Metastatic Solid Tumours.	Recruiting	N/A	35			Suzhou NeuPharma Co., Ltd., Suzhou NeuPharma Co., Ltd.	Advanced or Metastatic Solid Tumours